$GOSS

Gossamer Bio (GOSS) announced a private placement with up to $250M in gross proceeds, but only $25M is expected upfront. The remaining funds are contingent on regulatory milestones for seralutinib, a drug for pulmonary arterial hypertension. The company ended June with $57M in cash, expecting the initial $25M to improve near-term liquidity but not fully secure its runway.

Gossamer Bio (GOSS) granted its CCO 5.8M stock options. 50% vest upon FDA approval of seralutinib, with the rest vesting monthly over 24 months. If no approval within 2 years, vesting begins monthly over 24 months. Options expire in 2036 with a $0.175 exercise price.

Gossamer Bio secured up to $250M in financing, including $150M committed capital and $100M in potential warrants, to fund seralutinib through FDA approval for pulmonary arterial hypertension. The company plans to use the funds for clinical trials, potential commercialization, and corporate needs, aiming to submit an NDA in September 2026. Investors include EcoR1 Capital, 683 Capital Partners, and others.

Gossamer Bio (GOSS) plans a private placement of up to $250M, including $150M committed capital. The deal involves new and existing investors and is contingent on FDA actions for seralutinib. Latham & Watkins advised the company. The financing follows Gossamer's reacquisition of seralutinib rights and precedes its planned NDA submission in September 2026.

Gossamer Bio (GOSS) shares fell 5.59% after announcing a $250M financing deal tied to FDA milestones for seralutinib. The company plans to submit an NDA in September, with $150M committed and $100M contingent on approval. Analysts maintain Buy ratings with targets up to $4. Q2 revenue was $9.2M, R&D expenses $26.4M.

Gossamer Bio, Inc. (GOSS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval – $150 Million of Committed Capital: $25 Million Funded Upfront at Initial Closing, Plus an Additio

Gossamer Bio reported Q2 2026 net income of $16.9M and cash, cash equivalents and marketable securities of $57.0M as of June 30, 2026, citing non-operating gains from debt extinguishment. Revenue from collaborators was $9.2M. The company said it plans to submit an NDA for seralutinib in PAH in Sept 2026 and received FDA Pre-NDA Type B minutes. Shareholders approved a convertible note exchange and a potential reverse stock split.

Gossamer Bio, Inc. (GOSS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update - NDA Submission for Seralutinib in PAH On Track for September 2026 Following Receipt of Pre-NDA Type B Meeting Minutes - - Gossamer Reacquired Worldwide Development and Commerc

Biotech gainers included Entera Bio (ENTX), up 91% after an oversubscribed private placement expected to raise about $275M. Gossamer Bio (GOSS) rose 47% on plans to file a Seralutinib NDA for PAH in Sept 2026 and regain rights from Chiesi. Forte Biosciences (FBRX) jumped 40% on argenx (ARGX) acquisition for $77/share. Omeros (OMER) gained 16% after AstraZeneca’s Ultomiris failed a Phase 3 endpoint.

Gossamer Bio, Inc. (GOSS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-10.1 2 goss-20260727xex101xchiesi.htm EX-10.1 Document Exhibit 10.1 EXECUTION VERSION RIGHTS REACQUISITION AGREEMENT This RIGHTS REACQUISITION AGREEMENT (this “ Agreement ”) is entered into as of July 23, 2026 (the “ Rights Reacquisition Effective Date ”), by and among Chiesi